Press Release

Daewoong Pharmaceutical’s press release

NEW 1 Daewoong Pharmaceutical’s gastroesophageal reflux disease drug Fexuprazan obtained approval for a phase-3 trial in China: 2020-1230

NEW 2 Daewoong Pharmaceutical’s Nabota proves its efficacy in hair loss through clinical trials: 2020-1125

NEW 3 Daewoong Pharmaceutical’s Foistar Tab expected to be released as treatment for COVID-19 in January 2021: 2020-1123

Daewoong Pharmaceutical’s gastroesophageal reflux disease drug Fexuprazan obtained approval for a phase-3 trial in China 2020-12-30
Daewoong Pharmaceutical’s Nabota proves its efficacy in hair loss through clinical trials 2020-11-25
Daewoong Pharmaceutical’s Foistar Tab expected to be released as treatment for COVID-19 in January 2021 2020-11-23
Daewoong Pharmaceutical’s subsidiary iN Therapeutics begins development of hearing loss treatment with AI drug company DEARGEN Inc. 2020-11-17
Daewoong Pharmaceutical’s Olostar proved its excellent blood pressure reduction effects… Published in an SCI-grade journal 2020-11-11
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study 2020-11-06
Daewoong Pharmaceutical obtains approval for phase-3 clinical trials in South Korea for third indications of new drug Enavogliflozin for diabetes treatment 2020-11-04
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide 2020-10-29
Daewoong Pharmaceutical’s Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 ‘Twindemic’ 2020-10-27

1 2 3 4 5 6 7 8 9 10 다음 페이지

Search